# Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."

> **NCT02581969** · — · COMPLETED · sponsor: **Bayer** · enrollment: 43 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- **DRUG:** Recombinant Factor VIII (Kogenate FS, BAY14-2222)

## Key facts

- **NCT ID:** NCT02581969
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-14
- **Primary completion:** 2017-03-16
- **Final completion:** 2018-06-21
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2020-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02581969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02581969, "Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02581969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*